Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany.

Sinn M, Bischoff S, Nehls O, Pelzer U, von Weizsäcker F, Kubicka S, Stieler JM, Caca K, Riess H.

Onkologie. 2012;35(12):755-60. doi: 10.1159/000345115.

PMID:
23207621
3.

Patterns of practice in the radiation therapy management of rectal cancer: survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "Associazione Italiana di Radioterapia Oncologica (AIRO)".

Di Genesio Pagliuca M, Turri L, Munoz F, Melano A, Bacigalupo A, Franzone P, Sciacero P, Tseroni V, Vitali ML, Delmastro E, Scolaro T, Marziano C, Orsatti M, Tessa M, Rossi A, Ballare A, Moro G, Grasso R, Krengli M.

Tumori. 2013 Jan-Feb;99(1):61-7. doi: 10.1700/1248.13790.

PMID:
23549002
4.

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.

Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.

BMC Cancer. 2008 Dec 18;8:374. doi: 10.1186/1471-2407-8-374.

5.

Use of metronomic chemotherapy in oncology: results from a national Italian survey.

Collovà E, Sebastiani F, De Matteis E, Generali D, Aurilio G, Boccardo F, Crispino S, Cruciani G.

Tumori. 2011 Jul-Aug;97(4):454-8. doi: 10.1700/950.10397.

6.
7.

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H.

Eur J Cancer. 2011 Jul;47(11):1676-81. doi: 10.1016/j.ejca.2011.04.011.

PMID:
21565490
8.

Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.

Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS.

Cancer. 2005 Dec 15;104(12):2753-8.

10.

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.

Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8.

PMID:
17143602
11.

Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.

Woo SM, Lee WJ, Han SS, Park SJ, Kim TH, Koh YH, Kim HB, Hong EK, Park JW, Kim CM.

Chemotherapy. 2012;58(3):225-32. doi: 10.1159/000339499.

PMID:
22831988
12.

Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.

Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research..

J Clin Oncol. 2008 Aug 1;26(22):3702-8. doi: 10.1200/JCO.2008.16.5704.

PMID:
18669455
13.

Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.

Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K.

Invest New Drugs. 2011 Dec;29(6):1488-93. doi: 10.1007/s10637-010-9485-4.

PMID:
20607585
14.

Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.

Gunnlaugsson A, Anderson H, Lind P, Glimelius B, Johnsson A.

Radiother Oncol. 2010 Jun;95(3):292-7. doi: 10.1016/j.radonc.2010.04.004.

PMID:
20451275
15.

Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).

Link K, Happich K, Schirner I, Jüngert B, Brückl V, Männlein G, Brückl WM, Merkel S, Göhl J, Hohenberger W, Hahn EG, Wein A.

Anticancer Res. 2004 Jan-Feb;24(1):385-91.

16.

[Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms].

Grothey A, Kellermann L, Schmoll HJ.

Med Klin (Munich). 2002 May 15;97(5):270-7. German.

PMID:
12078387
17.

The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.

Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, Villa E.

Cancer. 2010 May 1;116(9):2208-14. doi: 10.1002/cncr.24970.

18.

Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: a mailed survey of pediatric oncologists.

Henderson TO, Hlubocky FJ, Wroblewski KE, Diller L, Daugherty CK.

J Clin Oncol. 2010 Feb 10;28(5):878-83. doi: 10.1200/JCO.2009.25.6107.

19.

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.

Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K.

Cancer. 2006 Mar 15;106(6):1339-46.

20.

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K; Xeloda Colorectal Cancer Study Group..

Eur J Cancer. 2001 Mar;37(5):597-604.

PMID:
11290435
Items per page

Supplemental Content

Support Center